Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advan...

Full description

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 31; no. 3; pp. 334 - 351
Main Authors Chen, L.-T., Martinelli, E., Cheng, A.-L., Pentheroudakis, G., Qin, S., Bhattacharyya, G.S., Ikeda, M., Lim, H.-Y., Ho, G.F., Choo, S.P., Ren, Z., Malhotra, H., Ueno, M., Ryoo, B.-Y., Kiang, T.C., Tai, D., Vogel, A., Cervantes, A., Lu, S.-N., Yen, C.-J., Huang, Y.-H., Chen, S.-C., Hsu, C., Shen, Y.-C., Tabernero, J., Yen, Y., Hsu, C.-H., Yoshino, T., Douillard, J.-Y.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.03.2020
Subjects
Asia
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - therapy
China
consensus
ESMO guidelines
HCC
hepatocellular carcinoma
Humans
India
Japan
Liver Neoplasms - diagnosis
Liver Neoplasms - therapy
Malaysia
Medical Oncology
Pan-Asian
Republic of Korea
Taiwan
Asia
China
Japan
Taiwan
Malaysia
Republic of Korea
India
consensus
HCC
Pan-Asian
ESMO guidelines
hepatocellular carcinoma
Online AccessGet full text
ISSN0923-7534
1569-8041
1569-8041
DOI10.1016/j.annonc.2019.12.001

Cover

Abstract The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.
AbstractList The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.
Author Martinelli, E.
Kiang, T.C.
Pentheroudakis, G.
Cervantes, A.
Choo, S.P.
Hsu, C.-H.
Yen, C.-J.
Qin, S.
Bhattacharyya, G.S.
Ikeda, M.
Douillard, J.-Y.
Malhotra, H.
Ueno, M.
Chen, L.-T.
Lim, H.-Y.
Huang, Y.-H.
Hsu, C.
Ho, G.F.
Yoshino, T.
Cheng, A.-L.
Yen, Y.
Ryoo, B.-Y.
Tabernero, J.
Tai, D.
Vogel, A.
Shen, Y.-C.
Ren, Z.
Lu, S.-N.
Chen, S.-C.
Author_xml – sequence: 1
  givenname: L.-T.
  surname: Chen
  fullname: Chen, L.-T.
  email: leochen@nhri.org.tw
  organization: National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
– sequence: 2
  givenname: E.
  surname: Martinelli
  fullname: Martinelli, E.
  organization: Department of Clinical and Experimental Medicine ‘F Magrassi’ – Medical Oncology, Università degli Studi della Campania L Vanvitelli, Naples, Italy
– sequence: 3
  givenname: A.-L.
  surname: Cheng
  fullname: Cheng, A.-L.
  organization: Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
– sequence: 4
  givenname: G.
  surname: Pentheroudakis
  fullname: Pentheroudakis, G.
  organization: Department of Medical Oncology, University of Ioannina, Ioannina, Greece
– sequence: 5
  givenname: S.
  surname: Qin
  fullname: Qin, S.
  organization: Chinese PLA Cancer Center, Jinling Hospital, Nanjing, China
– sequence: 6
  givenname: G.S.
  surname: Bhattacharyya
  fullname: Bhattacharyya, G.S.
  organization: Salt Lake City Medical Center, Kolkata, India
– sequence: 7
  givenname: M.
  surname: Ikeda
  fullname: Ikeda, M.
  organization: Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Japan
– sequence: 8
  givenname: H.-Y.
  surname: Lim
  fullname: Lim, H.-Y.
  organization: Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea
– sequence: 9
  givenname: G.F.
  surname: Ho
  fullname: Ho, G.F.
  organization: Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
– sequence: 10
  givenname: S.P.
  surname: Choo
  fullname: Choo, S.P.
  organization: Curie Oncology, Singapore; National Cancer Centre Singapore, Singapore, Singapore
– sequence: 11
  givenname: Z.
  surname: Ren
  fullname: Ren, Z.
  organization: Zhongshan Hospital, Fudan University, Shanghai, China
– sequence: 12
  givenname: H.
  surname: Malhotra
  fullname: Malhotra, H.
  organization: Department of Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi Medical College Hospital, Jaipur, India
– sequence: 13
  givenname: M.
  surname: Ueno
  fullname: Ueno, M.
  organization: Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
– sequence: 14
  givenname: B.-Y.
  surname: Ryoo
  fullname: Ryoo, B.-Y.
  organization: Department of Oncology, Asan Medical Center University of Ulsan College of Medicine, Seoul, South Korea
– sequence: 15
  givenname: T.C.
  surname: Kiang
  fullname: Kiang, T.C.
  organization: Hospital Umum Sarawak, Kuching, Sarawak, Malaysia
– sequence: 16
  givenname: D.
  surname: Tai
  fullname: Tai, D.
  organization: Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
– sequence: 17
  givenname: A.
  surname: Vogel
  fullname: Vogel, A.
  organization: Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
– sequence: 18
  givenname: A.
  surname: Cervantes
  fullname: Cervantes, A.
  organization: CIBERONC, Department of Medical Oncology, Institute of Health Research, INCLIVIA, University of Valencia, Valencia, Spain
– sequence: 19
  givenname: S.-N.
  surname: Lu
  fullname: Lu, S.-N.
  organization: Division of Hepato-Gastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
– sequence: 20
  givenname: C.-J.
  surname: Yen
  fullname: Yen, C.-J.
  organization: Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan
– sequence: 21
  givenname: Y.-H.
  surname: Huang
  fullname: Huang, Y.-H.
  organization: Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
– sequence: 22
  givenname: S.-C.
  surname: Chen
  fullname: Chen, S.-C.
  organization: Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
– sequence: 23
  givenname: C.
  surname: Hsu
  fullname: Hsu, C.
  organization: Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
– sequence: 24
  givenname: Y.-C.
  surname: Shen
  fullname: Shen, Y.-C.
  organization: Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
– sequence: 25
  givenname: J.
  surname: Tabernero
  fullname: Tabernero, J.
  organization: Medical Oncology Department, Vall d' Hebron University Hospital and Institute of Oncology (VHIO), UVic, IOB-Quiron, Barcelona, Spain
– sequence: 26
  givenname: Y.
  surname: Yen
  fullname: Yen, Y.
  organization: Taipei Medical University, Taipei, Taiwan
– sequence: 27
  givenname: C.-H.
  surname: Hsu
  fullname: Hsu, C.-H.
  organization: Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
– sequence: 28
  givenname: T.
  surname: Yoshino
  fullname: Yoshino, T.
  organization: Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Japan
– sequence: 29
  givenname: J.-Y.
  surname: Douillard
  fullname: Douillard, J.-Y.
  organization: ESMO, Lugano, Switzerland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32067677$$D View this record in MEDLINE/PubMed
BookMark eNqFUU1vEzEQtVAR_YB_gJCPHLqp7f3K9oBURaUUGm2kLWdr1jtLHO3aqe0E9cZ_4Pdx4ZfgJIUDB7h4RqP33ozfOyVHxhok5DVnE854cbGagIkjNRGMVxMuJozxZ-SE50WVTFnGj8gJq0SalHmaHZNT71eMsaIS1QtynApWlEVZnpAfCzDJlddgKHSwDtjR62Ze09mgjVYw0IUDFbRCerPRHcYpetpbR8MS6QgGvuCIJlDb0zUEHVtPv-qwpNoEdCN2GgJSMF2U34JR2F04HGDt46IlRopVOAybARxV4JQ2doRLCvS-bn5--74_JR4SooreIkXTWbejto901szqc3rbzBexfIzAc_pp_87rZr-waeqX5HkPg8dXT_WMfH5_fT_7kNzVN7ezq7tEpYUISclZIbIy7Vne5m2fq2rKo2sCy6xiJctyATDNC6HarG1bVqSgUh67iMISIU_PyNuD7trZhw36IEftdx8Dg3bjpUjzMit5llYR-uYJummjPXLt9AjuUf6OJAKyA0A5673D_g-EM7lLXq7kIXm5S15yIWPykXb5F03pEF2zJjjQw__I7w5kjCZtNTrpVcwypqUdqiA7q_8t8AtVyMyz
CitedBy_id crossref_primary_10_1007_s00330_022_08848_7
crossref_primary_10_1016_j_ctrv_2023_102526
crossref_primary_10_1111_jgh_16088
crossref_primary_10_1177_15330338211063848
crossref_primary_10_3389_fimmu_2024_1414121
crossref_primary_10_4254_wjh_v12_i11_1128
crossref_primary_10_1038_s43018_022_00357_2
crossref_primary_10_1111_hepr_13811
crossref_primary_10_1097_JS9_0000000000000652
crossref_primary_10_2147_JHC_S429352
crossref_primary_10_3350_cmh_2022_0421
crossref_primary_10_1002_14651858_CD015389
crossref_primary_10_1007_s00261_021_03349_5
crossref_primary_10_1186_s12909_024_05615_8
crossref_primary_10_1016_j_clinre_2024_102520
crossref_primary_10_1016_j_ebiom_2023_104962
crossref_primary_10_1111_hepr_14178
crossref_primary_10_1080_14796694_2024_2397328
crossref_primary_10_4103_JCRP_JCRP_21_21
crossref_primary_10_1186_s40644_023_00581_8
crossref_primary_10_1038_s41598_020_73930_3
crossref_primary_10_5582_bst_2024_01372
crossref_primary_10_17116_hirurgia202112134
crossref_primary_10_3389_fimmu_2022_892618
crossref_primary_10_4240_wjgs_v15_i4_544
crossref_primary_10_3390_jcm12103517
crossref_primary_10_1111_liv_15130
crossref_primary_10_1111_liv_15251
crossref_primary_10_1080_02656736_2023_2174709
crossref_primary_10_1080_07853890_2022_2081872
crossref_primary_10_2217_fon_2020_0986
crossref_primary_10_3748_wjg_v29_i11_1669
crossref_primary_10_3389_fonc_2022_928119
crossref_primary_10_1038_s41598_024_62523_z
crossref_primary_10_3348_kjr_2021_0229
crossref_primary_10_1016_j_ijsu_2021_106094
crossref_primary_10_3389_fimmu_2022_868809
crossref_primary_10_3389_fimmu_2024_1418965
crossref_primary_10_1016_j_ctrv_2022_102501
crossref_primary_10_3389_fphar_2023_1210835
crossref_primary_10_3390_cancers13194853
crossref_primary_10_2147_IJGM_S376919
crossref_primary_10_1016_j_rgmx_2022_01_006
crossref_primary_10_3390_cancers14184387
crossref_primary_10_3389_fonc_2022_1016952
crossref_primary_10_1007_s12072_023_10599_6
crossref_primary_10_1186_s13256_024_04928_y
crossref_primary_10_1055_s_0041_1730949
crossref_primary_10_2478_rjim_2022_0014
crossref_primary_10_3748_wjg_v30_i4_318
crossref_primary_10_2147_OTT_S332351
crossref_primary_10_1007_s00262_024_03872_6
crossref_primary_10_5582_bst_2022_01061
crossref_primary_10_1016_j_jvir_2021_07_025
crossref_primary_10_1136_bmjopen_2023_074245
crossref_primary_10_1097_CAD_0000000000001458
crossref_primary_10_3389_fbioe_2021_667641
crossref_primary_10_1016_j_esmoop_2021_100129
crossref_primary_10_1007_s10278_024_01003_2
crossref_primary_10_1159_000531820
crossref_primary_10_3748_wjg_v30_i19_2488
crossref_primary_10_1007_s00423_024_03249_4
crossref_primary_10_1200_JCO_21_01963
crossref_primary_10_1016_S0140_6736_22_01200_4
crossref_primary_10_1007_s12072_020_10073_7
crossref_primary_10_18528_ijgii210046
crossref_primary_10_1021_acs_molpharmaceut_1c00749
crossref_primary_10_1080_14656566_2023_2229728
crossref_primary_10_1007_s00330_023_09725_7
crossref_primary_10_14218_JCTH_2021_00017
crossref_primary_10_2147_CLEP_S352045
crossref_primary_10_1016_j_prmcm_2025_100581
crossref_primary_10_4081_oncol_2020_515
crossref_primary_10_3389_fimmu_2023_1100079
crossref_primary_10_1186_s12967_022_03277_y
crossref_primary_10_1002_jssc_70042
crossref_primary_10_1016_j_annonc_2020_01_064
crossref_primary_10_1007_s00432_024_05854_8
crossref_primary_10_2147_JHC_S411748
crossref_primary_10_1186_s12929_024_01011_y
crossref_primary_10_1186_s12916_022_02608_6
crossref_primary_10_3389_fimmu_2021_792781
crossref_primary_10_1007_s13105_023_00972_2
crossref_primary_10_1016_S2468_1253_24_00434_5
crossref_primary_10_1007_s12672_022_00559_1
crossref_primary_10_1016_j_jvir_2023_11_026
crossref_primary_10_1097_MD_0000000000028869
crossref_primary_10_1097_MD_0000000000027497
crossref_primary_10_1007_s12029_024_01089_5
crossref_primary_10_1177_17588359211002720
crossref_primary_10_4103_ijmr_IJMR_404_20
crossref_primary_10_3350_cmh_2020_0204
crossref_primary_10_2147_JHC_S220978
crossref_primary_10_1055_s_0044_1788691
crossref_primary_10_1016_j_ultrasmedbio_2023_10_008
crossref_primary_10_3390_cancers13112626
crossref_primary_10_3389_fimmu_2021_690869
crossref_primary_10_3389_fimmu_2024_1430196
crossref_primary_10_3389_fonc_2024_1431069
crossref_primary_10_1158_1078_0432_CCR_23_0060
crossref_primary_10_2147_CMAR_S440017
crossref_primary_10_3389_fonc_2022_807189
crossref_primary_10_3389_fonc_2024_1344798
crossref_primary_10_1002_jbt_70148
crossref_primary_10_1016_j_jvir_2020_07_024
crossref_primary_10_3389_fimmu_2024_1471017
crossref_primary_10_3389_fpubh_2024_1356244
crossref_primary_10_1016_j_livres_2025_01_002
crossref_primary_10_3389_pore_2022_1610808
crossref_primary_10_3389_fphar_2023_1219694
crossref_primary_10_1007_s00432_024_05795_2
crossref_primary_10_1111_hepr_14007
crossref_primary_10_1016_j_iliver_2022_10_001
crossref_primary_10_1186_s12893_025_02778_z
crossref_primary_10_1111_hepr_13708
crossref_primary_10_4251_wjgo_v16_i6_2380
crossref_primary_10_1002_aid2_13277
crossref_primary_10_1002_cam4_70396
crossref_primary_10_1016_j_iliver_2023_03_002
crossref_primary_10_3389_fonc_2021_773045
crossref_primary_10_1080_17843286_2022_2076791
crossref_primary_10_2139_ssrn_4000456
crossref_primary_10_37174_2587_7593_2023_6_4_62_67
crossref_primary_10_1016_j_ejmech_2024_116978
crossref_primary_10_1016_j_acra_2023_05_014
crossref_primary_10_1007_s00330_022_08811_6
crossref_primary_10_1016_j_rgmxen_2022_01_004
crossref_primary_10_1200_JCO_22_00392
crossref_primary_10_3389_fimmu_2021_634559
crossref_primary_10_3748_wjg_v27_i13_1330
crossref_primary_10_1001_jamaoncol_2023_4003
crossref_primary_10_1159_000508901
crossref_primary_10_1097_JS9_0000000000000683
crossref_primary_10_2147_JHC_S316117
crossref_primary_10_3389_fonc_2024_1293680
crossref_primary_10_3389_fphar_2024_1410767
crossref_primary_10_1097_PPO_0000000000000684
crossref_primary_10_1002_hep4_2025
crossref_primary_10_3389_fonc_2022_882272
crossref_primary_10_1016_j_hpb_2022_04_007
crossref_primary_10_1039_D0RA06415G
crossref_primary_10_14218_JCTH_2021_00179
crossref_primary_10_1097_JS9_0000000000001889
crossref_primary_10_1159_000529676
crossref_primary_10_1007_s10462_021_10023_1
crossref_primary_10_1007_s12029_023_00961_0
crossref_primary_10_1186_s12935_021_01871_6
Cites_doi 10.1001/jamaoncol.2019.0250
10.5582/bst.2017.01202
10.1016/S1470-2045(09)70241-4
10.1200/JCO.2012.45.8372
10.4254/wjh.v7.i12.1708
10.1053/j.gastro.2016.08.029
10.1016/S0140-6736(02)08649-X
10.1111/jgh.13586
10.1177/2050640616673516
10.1016/j.jhep.2017.11.007
10.1177/2050640617716597
10.1007/s00261-012-9952-9
10.1016/j.jfma.2017.09.007
10.1159/000368000
10.1016/S0140-6736(17)31046-2
10.1056/NEJM199306243282501
10.1016/j.jhep.2018.11.029
10.1002/hep.22709
10.1093/annonc/mds605
10.1053/jhep.2003.50047
10.1016/j.jhep.2017.07.025
10.1186/s12876-017-0656-z
10.1093/annonc/mdx738
10.1016/j.jhep.2016.01.012
10.1016/S0140-6736(16)32453-9
10.1111/j.1440-1746.2012.07132.x
10.1038/bjc.2013.85
10.1016/j.jhep.2009.12.028
10.1007/s12072-009-9145-y
10.5009/gnl19024
10.1016/S2468-1253(17)30156-5
10.1002/hep.26382
10.1200/JCO.2018.36.4_suppl.207
10.1200/JCO.2017.76.0892
10.1016/j.jhep.2011.03.007
10.1200/JCO.2012.44.5643
10.1159/000367755
10.1038/nrgastro.2014.67
10.1136/gut.2008.149062
10.1016/j.ejso.2017.11.022
10.1093/annonc/mdy308
10.1016/j.jhep.2011.11.022
10.1016/j.cld.2011.03.006
10.1159/000488035
10.1093/annonc/mdw323
10.1002/hep.27290
10.1159/000368142
10.1055/s-0030-1247132
10.1159/000452138
10.1371/journal.pone.0133488
10.1002/hep.22742
10.1007/s12072-011-9322-7
10.1086/321805
10.1038/bjc.2011.360
10.1016/S2468-1253(18)30078-5
10.1001/jamaoncol.2017.5847
10.1148/radiol.14140690
10.1002/jmri.23685
10.1016/j.jhep.2014.04.046
10.1016/j.jhep.2014.08.045
10.1053/j.gastro.2012.10.001
10.1002/hep.26487
10.1002/cncr.24884
10.1016/S0168-8278(18)30424-0
10.1002/hep.21966
10.1200/JCO.2006.08.4046
10.1111/j.1365-2753.2010.01432.x
10.1038/bjc.2013.542
10.1200/JCO.2014.57.9151
10.1371/journal.pone.0100305
10.1007/s00270-006-0062-3
10.1002/hep.29363
10.1001/jama.295.1.65
10.1016/S1470-2045(08)70285-7
10.1002/hep.1840130303
10.1053/j.gastro.2012.02.007
10.1007/s00432-004-0552-0
10.1016/S1470-2045(18)30351-6
10.2214/AJR.10.5390
10.1159/000449336
10.1093/annonc/mdx310
10.3322/caac.21492
10.1007/s00270-009-9750-0
10.1053/j.gastro.2014.02.032
10.1016/S2468-1253(17)30290-X
10.1016/S1470-2045(18)30937-9
10.1053/j.gastro.2010.10.049
10.1148/radiol.11110282
10.1111/j.1872-034X.2011.00936.x
10.1007/s00261-011-9685-1
10.1016/j.jhep.2017.01.012
10.1159/000343875
10.1186/s40644-016-0062-8
10.1056/NEJMoa0708857
10.1016/S1470-2045(17)30074-8
10.1016/j.jhep.2015.05.022
10.1111/liv.13359
10.1053/jhep.2002.33156
10.1056/NEJM199706263362602
10.1016/S0002-9343(96)00197-0
10.1016/j.jhep.2017.06.026
10.1007/s00280-018-3638-0
10.1097/SLA.0000000000001460
10.1007/s12072-017-9799-9
10.1002/hep.26703
10.1093/jnci/dji315
10.1200/JCO.2013.53.7746
10.1016/S0140-6736(18)30207-1
10.1111/liv.13719
10.1002/hep.29883
10.1111/jgh.14152
10.1200/JCO.2015.64.0821
10.1002/hep.26014
10.1200/JCO.2013.54.3298
10.1200/JCO.2012.48.4410
10.1111/j.1600-6143.2009.02695.x
10.1007/s00259-017-3880-4
10.1016/j.ejca.2011.05.007
10.1016/S1470-2045(17)30683-6
10.1007/s00270-009-9711-7
ContentType Journal Article
Copyright 2020 European Society for Medical Oncology
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2020 European Society for Medical Oncology
– notice: Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.annonc.2019.12.001
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1569-8041
EndPage 351
ExternalDocumentID 32067677
10_1016_j_annonc_2019_12_001
S0923753419532240
Genre Practice Guideline
GeographicLocations Asia
China
Japan
Taiwan
Malaysia
Republic of Korea
India
GeographicLocations_xml – name: Republic of Korea
– name: Taiwan
– name: Asia
– name: India
– name: Japan
– name: China
– name: Malaysia
GroupedDBID ---
-E4
.2P
.86
.I3
.XZ
.ZR
08P
0R~
0U7
1TH
23M
2WC
4.4
482
48X
53G
5GY
5VS
5WA
6.Y
6I.
6J9
70D
AABJS
AABMN
AAEDW
AAESY
AAFTH
AAIAV
AAIYJ
AAJKP
AAJQQ
AAKAS
AAKUH
AAMVS
AAOGV
AAPNW
AAUQX
AAXUO
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNKS
ABOCM
ABQLI
ABQTQ
ABSAR
ABSMQ
ABVKL
ABZBJ
ACGFO
ACGFS
ACIMA
ACMRT
ACPQN
ACPRK
ACUFI
ACUTO
ADBBV
ADEIU
ADEYI
ADHKW
ADHZD
ADJQC
ADOCK
ADORX
ADQLU
ADRIX
ADRTK
ADYVW
ADZCM
ADZXQ
AEGPL
AEGXH
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AEWNT
AFIYH
AFOFC
AFXEN
AGINJ
AGKEF
AGKRT
AGSYK
AHMBA
AHXPO
AIAGR
AIJHB
AIKOY
AITUG
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AMRAJ
APIBT
APWMN
AQKUS
ASMCH
ASPBG
ATTQO
AVWKF
AWCFO
AXUDD
AZFZN
AZQFJ
BAWUL
BAYMD
BEYMZ
BGNMA
BGYMP
BHONS
BTRTY
BVRKM
BZKNY
C1A
CAG
CASEJ
CDBKE
CKLRP
COF
CS3
CZ4
DAKXR
DIK
DILTD
DL5
DPORF
DPPUQ
D~K
E3Z
EBS
EE~
EJD
EX3
F9B
FDB
FEDTE
GJXCC
GX1
H5~
HAR
HVGLF
HW0
HZ~
I09
IH2
IHE
IOX
J21
KAQDR
KC5
KDC
KOM
KOP
KQ8
KSI
KSN
LAK
M-Z
M41
M49
M4Y
MBLQV
MHKGH
N9A
NCXOZ
NGC
NOYVH
NTWIH
NU-
NU0
NVLIB
O9-
OAWHX
ODMLO
OJQWA
OK1
OVD
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RNI
ROL
ROX
ROZ
RPX
RW1
RXO
RZC
RZE
RZF
RZO
SDH
TCURE
TEORI
TJX
TMA
TR2
U2A
W8F
WOQ
WOW
X7H
YAYTL
YFH
YKOAZ
ZKX
ZXP
~91
AAGQS
AALRI
AAYWO
AAYXX
ABNGD
ACUKT
ACVFH
ADCNI
ADVLN
AEHUL
AEUPX
AFETI
AFJKZ
AFPUW
AFSHK
AGCQF
AGQPQ
AIGII
AKBMS
AKRWK
AKYEP
APXCP
CITATION
H13
CGR
CUY
CVF
ECM
EIF
NPM
7X8
EFKBS
ID FETCH-LOGICAL-c362t-71062473f05b5bf5c9815342e749070452aa8562cb4bbb063ac31bbb815e7ea53
ISSN 0923-7534
1569-8041
IngestDate Sun Sep 28 11:42:32 EDT 2025
Wed Feb 19 02:29:41 EST 2025
Thu Apr 24 22:57:09 EDT 2025
Tue Jul 01 02:10:02 EDT 2025
Fri Feb 23 02:43:41 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords consensus
HCC
Pan-Asian
ESMO guidelines
hepatocellular carcinoma
Language English
License This article is made available under the Elsevier license.
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c362t-71062473f05b5bf5c9815342e749070452aa8562cb4bbb063ac31bbb815e7ea53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Instructional Material/Guideline-2
ObjectType-Feature-3
content type line 23
OpenAccessLink https://dx.doi.org/10.1016/j.annonc.2019.12.001
PMID 32067677
PQID 2357471439
PQPubID 23479
PageCount 18
ParticipantIDs proquest_miscellaneous_2357471439
pubmed_primary_32067677
crossref_primary_10_1016_j_annonc_2019_12_001
crossref_citationtrail_10_1016_j_annonc_2019_12_001
elsevier_sciencedirect_doi_10_1016_j_annonc_2019_12_001
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2020
2020-03-00
20200301
PublicationDateYYYYMMDD 2020-03-01
PublicationDate_xml – month: 03
  year: 2020
  text: March 2020
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Annals of oncology
PublicationTitleAlternate Ann Oncol
PublicationYear 2020
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Kim, Kim, Wang (bib47) 2016; 264
Lewandowski, Kulik, Riaz (bib75) 2009; 9
Malagari, Pomoni, Kelekis (bib61) 2010; 33
Waziry, Hajarizadeh, Grebely (bib21) 2017; 67
Yoon, Ryoo, Lee (bib115) 2018; 4
Ashtari, Pourhoseingholi, Sharifian, Zali (bib7) 2015; 7
Salem, Mazzaferro, Sangro (bib72) 2013; 58
Hatooka, Kawaoka, Aikata (bib95) 2016; 36
Bartolozzi, Battaglia, Bargellini (bib35) 2013; 38
Mazzaferro, Sposito, Bhoori (bib80) 2013; 57
Zhu, Rosmorduc, Evans (bib103) 2015; 33
Zhang, Yang, Tang (bib28) 2004; 130
Kudo, Finn, Qin (bib104) 2018; 391
(bib111) 2019
Augustin, Pons, Maurice (bib51) 2017; 66
Salem, Gordon, Mouli (bib76) 2016; 151
Nouso, Kariyama, Nakamura (bib86) 2017; 32
Fuks, Cauchy, Fusco (bib40) 2014; 61
Wang, Chuah, Lu (bib45) 2012; 27
Boussouar, Itti, Lin (bib49) 2016; 16
Chen, Yang, Su (bib26) 2006; 295
Yeo, Mok, Zee (bib89) 2005; 97
Lo, Ngan, Tso (bib54) 2002; 35
Surveillance group, Diagnosis group, Staging group (bib11) 2018; 117
Omata, Cheng, Kokudo (bib6) 2017; 11
Nouso, Miyahara, Uchida (bib92) 2013; 109
Glantzounis, Paliouras, Stylianidi (bib84) 2018; 44
Facciorusso, Bellanti, Villani (bib57) 2017; 5
Papatheodoridis, Dalekos, Yurdaydin (bib20) 2015; 62
Lee, Lee, Lee (bib33) 2015; 275
Llovet, Bruix (bib55) 2003; 37
Matsui, Kobayashi, Sanada (bib34) 2011; 36
(bib15) 2019
Tanaka, Iijima, Nouso (bib23) 2012; 42
Prajapati, Spivey, Hanish (bib117) 2013; 24
Llovet, Real, Montana (bib53) 2002; 359
Lee, Huo, Huang (bib114) 2012; 6
Marelli, Stigliano, Triantos (bib58) 2007; 30
Vogel, Cervantes, Chau (bib3) 2018; 29
Choi, Chung, Bae (bib94) 2018; 82
Llovet, Ricci, Mazzaferro (bib63) 2008; 359
Zhang, Hu, Chen, Bie (bib64) 2014; 9
Lencioni, Montal, Torres (bib120) 2017; 66
Cheng, Qin, Ikeda (bib105) 2019
Meyer, Palmer, Cheng (bib121) 2017; 37
Kudo, Matsui, Izumi (bib81) 2014; 87
Kirstein, Voigtlander, Schweitzer (bib71) 2018; 6
Lin, Cheng, Chen, Lin (bib85) 2016; 5
Golfieri, Grazioli, Orlando (bib36) 2012; 36
Vouche, Kulik, Atassi (bib122) 2013; 58
He, Li, Zou (bib98) 2019; 5
Song, Cai, Tang (bib10) 2017; 11
Shim, Lee, Kim (bib118) 2012; 262
Yeh, Hu, Cho (bib30) 2014; 59
Gish, Porta, Lazar (bib87) 2007; 25
Kim, Shim, Yoon (bib113) 2018; 38
Kudo, Cheng, Park (bib66) 2018; 3
Tsukuma, Hiyama, Tanaka (bib25) 1993; 328
Kumada, Toyoda, Tada (bib37) 2011; 197
Cucchetti, Trevisani, Cescon (bib31) 2012; 56
Chang, Chen, Lai (bib18) 1997; 336
Lencioni, Llovet, Han (bib69) 2016; 64
Chow, Gandhi, Tan (bib74) 2018; 36
Cainap, Qin, Huang (bib101) 2015; 33
Terzi, Iavarone, Pompili (bib39) 2018; 68
Carr, Kondragunta, Buch, Branch (bib79) 2010; 116
Lammer, Malagari, Vogl (bib56) 2010; 33
Berzigotti, Seijo, Arena (bib46) 2013; 144
De Franchis (bib48) 2015; 63
Johnson, Qin, Park (bib102) 2013; 31
Bettinger, Spode, Glaser (bib112) 2017; 17
Kudo, Imanaka, Chida (bib68) 2011; 47
Rockey, Caldwell, Goodman (bib41) 2009; 49
El-Khoueiry, Sangro, Yau (bib109) 2017; 389
Zhu, Finn, Edeline (bib110) 2018; 19
Tseng, Liu, Yang (bib27) 2012; 142
Gillmore, Stuart, Kirkwood (bib116) 2011; 55
Park, Kim, Kim (bib70) 2019; 70
Chang, Lairson, Chan (bib24) 2011; 17
Bruix, Cheng, Meinhardt (bib91) 2017; 67
Silva, Hegab, Hyde (bib42) 2008; 57
Vilgrain, Pereira, Assenat (bib73) 2017; 18
McGlynn, London (bib2) 2011; 15
Hyun, Lee, Kim (bib83) 2018; 68
Zhu, Kang, Yen (bib108) 2019; 20
Mamdani, Wu, O'Neil, Sehdev (bib123) 2017; 23
Qin, Bai, Lim (bib88) 2013; 31
Ho, Hasegawa, Chen (bib82) 2016; 5
Yoon, Lee, Yang (bib38) 2014; 32
Bruix, Qin, Merle (bib106) 2017; 389
Chapiro, Ceschwind (bib52) 2014; 11
Sato, Tateishi, Yoshida (bib29) 2009; 3
Kudo, Han, Finn (bib67) 2014; 60
Kodama, Kawaoka, Aikata (bib93) 2018; 33
Cardoso, Moucari, Figueiredo-Mendes (bib19) 2010; 52
Yoshino, Arnold, Taniguchi (bib16) 2018; 29
Yau, Tang, Yao (bib14) 2014; 146
Hyun, Eo, Song (bib50) 2018; 45
Cheng, Kang, Lin (bib100) 2013; 31
Brown, Do, Gonen (bib60) 2016; 34
Bray, Ferlay, Soerjomataram (bib1) 2018; 68
Dykewicz (bib17) 2001; 33
Cheng, Kang, Chen (bib62) 2009; 10
(bib43) 2009; 49
Vincenzi, Di Maio, Silletta (bib119) 2015; 10
Salem, Lewandowski, Kulik (bib77) 2011; 140
(bib8) 2019; 13
Ikeda, Shimizu, Sato (bib97) 2016; 27
Abou-Alfa, Meyer, Cheng (bib107) 2018; 36
Johnson, Berhane, Kagebayashi (bib44) 2015; 33
Kudo, Matsui, Izumi (bib9) 2014; 3
Lencioni, Llovet (bib90) 2010; 30
Zhou, Sun, Wang (bib12) 2018; 7
Forner, Vilana, Ayuso (bib32) 2008; 47
Meyer, Kirkwood, Roughton (bib59) 2013; 108
Cherny, Dafni, Bogaerts (bib125) 2017; 28
Kudo, Ueshima, Yokosuka (bib96) 2018; 3
Meyer, Fox, Ma (bib65) 2017; 2
Chen, Liang, Chang (bib4) 1991; 13
Koh, Robien, Wang (bib5) 2011; 105
Seymour, Bogaerts, Perrone (bib124) 2017; 18
Sarasin, Giostra, Hadengue (bib22) 1996; 101
Poon, Anderson, Chen (bib13) 2009; 10
Kudo (bib99) 2017; 6
Ricke, Sangro, Amthauer (bib78) 2018; 68
Johnson (10.1016/j.annonc.2019.12.001_bib44) 2015; 33
Lin (10.1016/j.annonc.2019.12.001_bib85) 2016; 5
Qin (10.1016/j.annonc.2019.12.001_bib88) 2013; 31
Kudo (10.1016/j.annonc.2019.12.001_bib99) 2017; 6
Bray (10.1016/j.annonc.2019.12.001_bib1) 2018; 68
Cheng (10.1016/j.annonc.2019.12.001_bib62) 2009; 10
Hyun (10.1016/j.annonc.2019.12.001_bib83) 2018; 68
Llovet (10.1016/j.annonc.2019.12.001_bib53) 2002; 359
Kudo (10.1016/j.annonc.2019.12.001_bib9) 2014; 3
Cucchetti (10.1016/j.annonc.2019.12.001_bib31) 2012; 56
Chow (10.1016/j.annonc.2019.12.001_bib74) 2018; 36
Choi (10.1016/j.annonc.2019.12.001_bib94) 2018; 82
De Franchis (10.1016/j.annonc.2019.12.001_bib48) 2015; 63
Johnson (10.1016/j.annonc.2019.12.001_bib102) 2013; 31
Papatheodoridis (10.1016/j.annonc.2019.12.001_bib20) 2015; 62
Lee (10.1016/j.annonc.2019.12.001_bib33) 2015; 275
Zhang (10.1016/j.annonc.2019.12.001_bib28) 2004; 130
Kodama (10.1016/j.annonc.2019.12.001_bib93) 2018; 33
Zhou (10.1016/j.annonc.2019.12.001_bib12) 2018; 7
Sato (10.1016/j.annonc.2019.12.001_bib29) 2009; 3
Golfieri (10.1016/j.annonc.2019.12.001_bib36) 2012; 36
Bartolozzi (10.1016/j.annonc.2019.12.001_bib35) 2013; 38
Terzi (10.1016/j.annonc.2019.12.001_bib39) 2018; 68
Lo (10.1016/j.annonc.2019.12.001_bib54) 2002; 35
Gillmore (10.1016/j.annonc.2019.12.001_bib116) 2011; 55
Yeh (10.1016/j.annonc.2019.12.001_bib30) 2014; 59
Yoon (10.1016/j.annonc.2019.12.001_bib115) 2018; 4
Hyun (10.1016/j.annonc.2019.12.001_bib50) 2018; 45
Lencioni (10.1016/j.annonc.2019.12.001_bib120) 2017; 66
Lee (10.1016/j.annonc.2019.12.001_bib114) 2012; 6
(10.1016/j.annonc.2019.12.001_bib8) 2019; 13
Kirstein (10.1016/j.annonc.2019.12.001_bib71) 2018; 6
Berzigotti (10.1016/j.annonc.2019.12.001_bib46) 2013; 144
Lammer (10.1016/j.annonc.2019.12.001_bib56) 2010; 33
Tanaka (10.1016/j.annonc.2019.12.001_bib23) 2012; 42
Dykewicz (10.1016/j.annonc.2019.12.001_bib17) 2001; 33
Yeo (10.1016/j.annonc.2019.12.001_bib89) 2005; 97
Gish (10.1016/j.annonc.2019.12.001_bib87) 2007; 25
Nouso (10.1016/j.annonc.2019.12.001_bib86) 2017; 32
Chang (10.1016/j.annonc.2019.12.001_bib18) 1997; 336
Glantzounis (10.1016/j.annonc.2019.12.001_bib84) 2018; 44
Zhu (10.1016/j.annonc.2019.12.001_bib103) 2015; 33
Kudo (10.1016/j.annonc.2019.12.001_bib66) 2018; 3
El-Khoueiry (10.1016/j.annonc.2019.12.001_bib109) 2017; 389
Kudo (10.1016/j.annonc.2019.12.001_bib67) 2014; 60
Fuks (10.1016/j.annonc.2019.12.001_bib40) 2014; 61
Park (10.1016/j.annonc.2019.12.001_bib70) 2019; 70
Song (10.1016/j.annonc.2019.12.001_bib10) 2017; 11
Ashtari (10.1016/j.annonc.2019.12.001_bib7) 2015; 7
Meyer (10.1016/j.annonc.2019.12.001_bib59) 2013; 108
Kudo (10.1016/j.annonc.2019.12.001_bib96) 2018; 3
Malagari (10.1016/j.annonc.2019.12.001_bib61) 2010; 33
Brown (10.1016/j.annonc.2019.12.001_bib60) 2016; 34
Vincenzi (10.1016/j.annonc.2019.12.001_bib119) 2015; 10
Vogel (10.1016/j.annonc.2019.12.001_bib3) 2018; 29
Salem (10.1016/j.annonc.2019.12.001_bib76) 2016; 151
Lewandowski (10.1016/j.annonc.2019.12.001_bib75) 2009; 9
Bruix (10.1016/j.annonc.2019.12.001_bib106) 2017; 389
Cheng (10.1016/j.annonc.2019.12.001_bib105) 2019
Cardoso (10.1016/j.annonc.2019.12.001_bib19) 2010; 52
Tsukuma (10.1016/j.annonc.2019.12.001_bib25) 1993; 328
Hatooka (10.1016/j.annonc.2019.12.001_bib95) 2016; 36
Cherny (10.1016/j.annonc.2019.12.001_bib125) 2017; 28
Mazzaferro (10.1016/j.annonc.2019.12.001_bib80) 2013; 57
Kumada (10.1016/j.annonc.2019.12.001_bib37) 2011; 197
Vouche (10.1016/j.annonc.2019.12.001_bib122) 2013; 58
Cheng (10.1016/j.annonc.2019.12.001_bib100) 2013; 31
Surveillance group (10.1016/j.annonc.2019.12.001_bib11) 2018; 117
Chang (10.1016/j.annonc.2019.12.001_bib24) 2011; 17
Lencioni (10.1016/j.annonc.2019.12.001_bib90) 2010; 30
Zhu (10.1016/j.annonc.2019.12.001_bib110) 2018; 19
Llovet (10.1016/j.annonc.2019.12.001_bib55) 2003; 37
Bruix (10.1016/j.annonc.2019.12.001_bib91) 2017; 67
Forner (10.1016/j.annonc.2019.12.001_bib32) 2008; 47
Wang (10.1016/j.annonc.2019.12.001_bib45) 2012; 27
He (10.1016/j.annonc.2019.12.001_bib98) 2019; 5
McGlynn (10.1016/j.annonc.2019.12.001_bib2) 2011; 15
Kim (10.1016/j.annonc.2019.12.001_bib47) 2016; 264
(10.1016/j.annonc.2019.12.001_bib43) 2009; 49
Poon (10.1016/j.annonc.2019.12.001_bib13) 2009; 10
Facciorusso (10.1016/j.annonc.2019.12.001_bib57) 2017; 5
Salem (10.1016/j.annonc.2019.12.001_bib77) 2011; 140
Kudo (10.1016/j.annonc.2019.12.001_bib68) 2011; 47
Nouso (10.1016/j.annonc.2019.12.001_bib92) 2013; 109
Ikeda (10.1016/j.annonc.2019.12.001_bib97) 2016; 27
Waziry (10.1016/j.annonc.2019.12.001_bib21) 2017; 67
Cainap (10.1016/j.annonc.2019.12.001_bib101) 2015; 33
Yoshino (10.1016/j.annonc.2019.12.001_bib16) 2018; 29
Kim (10.1016/j.annonc.2019.12.001_bib113) 2018; 38
Prajapati (10.1016/j.annonc.2019.12.001_bib117) 2013; 24
Kudo (10.1016/j.annonc.2019.12.001_bib104) 2018; 391
Lencioni (10.1016/j.annonc.2019.12.001_bib69) 2016; 64
Yoon (10.1016/j.annonc.2019.12.001_bib38) 2014; 32
Vilgrain (10.1016/j.annonc.2019.12.001_bib73) 2017; 18
Sarasin (10.1016/j.annonc.2019.12.001_bib22) 1996; 101
Matsui (10.1016/j.annonc.2019.12.001_bib34) 2011; 36
Yau (10.1016/j.annonc.2019.12.001_bib14) 2014; 146
Chen (10.1016/j.annonc.2019.12.001_bib4) 1991; 13
Zhu (10.1016/j.annonc.2019.12.001_bib108) 2019; 20
Koh (10.1016/j.annonc.2019.12.001_bib5) 2011; 105
Omata (10.1016/j.annonc.2019.12.001_bib6) 2017; 11
Chen (10.1016/j.annonc.2019.12.001_bib26) 2006; 295
Augustin (10.1016/j.annonc.2019.12.001_bib51) 2017; 66
Bettinger (10.1016/j.annonc.2019.12.001_bib112) 2017; 17
Ricke (10.1016/j.annonc.2019.12.001_bib78) 2018; 68
Mamdani (10.1016/j.annonc.2019.12.001_bib123) 2017; 23
Salem (10.1016/j.annonc.2019.12.001_bib72) 2013; 58
Abou-Alfa (10.1016/j.annonc.2019.12.001_bib107) 2018; 36
Zhang (10.1016/j.annonc.2019.12.001_bib64) 2014; 9
Boussouar (10.1016/j.annonc.2019.12.001_bib49) 2016; 16
Llovet (10.1016/j.annonc.2019.12.001_bib63) 2008; 359
Meyer (10.1016/j.annonc.2019.12.001_bib65) 2017; 2
Marelli (10.1016/j.annonc.2019.12.001_bib58) 2007; 30
Seymour (10.1016/j.annonc.2019.12.001_bib124) 2017; 18
Chapiro (10.1016/j.annonc.2019.12.001_bib52) 2014; 11
Carr (10.1016/j.annonc.2019.12.001_bib79) 2010; 116
Shim (10.1016/j.annonc.2019.12.001_bib118) 2012; 262
Rockey (10.1016/j.annonc.2019.12.001_bib41) 2009; 49
Ho (10.1016/j.annonc.2019.12.001_bib82) 2016; 5
Meyer (10.1016/j.annonc.2019.12.001_bib121) 2017; 37
Kudo (10.1016/j.annonc.2019.12.001_bib81) 2014; 87
Tseng (10.1016/j.annonc.2019.12.001_bib27) 2012; 142
Silva (10.1016/j.annonc.2019.12.001_bib42) 2008; 57
32122696 - Ann Oncol. 2020 Apr;31(4):449-450
References_xml – volume: 29
  start-page: iv238
  year: 2018
  end-page: iv255
  ident: bib3
  article-title: Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
– volume: 64
  start-page: 1090
  year: 2016
  end-page: 1098
  ident: bib69
  article-title: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial
  publication-title: J Hepatol
– volume: 105
  start-page: 1430
  year: 2011
  end-page: 1435
  ident: bib5
  article-title: Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study
  publication-title: Br J Cancer
– volume: 57
  start-page: 1826
  year: 2013
  end-page: 1837
  ident: bib80
  article-title: Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study
  publication-title: Hepatology
– volume: 32
  start-page: 695
  year: 2017
  end-page: 700
  ident: bib86
  article-title: Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma
  publication-title: J Gastroenterol Hepatol
– volume: 6
  start-page: 238
  year: 2018
  end-page: 246
  ident: bib71
  article-title: Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
  publication-title: United European Gastroenterol J
– volume: 13
  start-page: 398
  year: 1991
  end-page: 406
  ident: bib4
  article-title: Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma
  publication-title: Hepatology
– volume: 33
  start-page: 172
  year: 2015
  end-page: 179
  ident: bib101
  article-title: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
  publication-title: J Clin Oncol
– volume: 68
  start-page: S102
  year: 2018
  ident: bib78
  article-title: The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the Soramic trial paliative cohort
  publication-title: J Hepatol
– volume: 11
  start-page: 317
  year: 2017
  end-page: 370
  ident: bib6
  article-title: Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
  publication-title: Hepatol Int
– volume: 359
  start-page: 378
  year: 2008
  end-page: 390
  ident: bib63
  article-title: Sorafenib in advanced hepatocellular carcinoma
  publication-title: N Engl J Med
– volume: 7
  start-page: 1708
  year: 2015
  end-page: 1717
  ident: bib7
  article-title: Hepatocellular carcinoma in Asia: prevention strategy and planning
  publication-title: World J Hepatol
– volume: 32
  start-page: 678
  year: 2014
  end-page: 689
  ident: bib38
  article-title: Non-hypervascular hypointense nodules ≥1 cm on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in cirrhotic livers
  publication-title: Dig Dis
– volume: 2
  start-page: 565
  year: 2017
  end-page: 575
  ident: bib65
  article-title: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
  publication-title: Lancet Gastroenterol Hepatol
– volume: 47
  start-page: 97
  year: 2008
  end-page: 104
  ident: bib32
  article-title: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
  publication-title: Hepatology
– volume: 27
  start-page: 1213
  year: 2012
  end-page: 1218
  ident: bib45
  article-title: Transient elastography and simple blood markers in the diagnosis of oesophageal varices for compensated patients with hepatitis B virus-related cirrhosis
  publication-title: J Gasterenterol Hepatol
– volume: 87
  start-page: 22
  year: 2014
  end-page: 31
  ident: bib81
  article-title: Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update
  publication-title: Oncology
– volume: 68
  start-page: 394
  year: 2018
  end-page: 424
  ident: bib1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
– volume: 55
  start-page: 1309
  year: 2011
  end-page: 1316
  ident: bib116
  article-title: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization
  publication-title: J Hepatol
– volume: 7
  start-page: 235
  year: 2018
  end-page: 260
  ident: bib12
  article-title: Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition)
  publication-title: Liver Cancer
– volume: 6
  start-page: 101
  year: 2017
  end-page: 112
  ident: bib99
  article-title: Molecular targeted agents for hepatocellular carcinoma: current status and future perspectives
  publication-title: Liver Cancer
– volume: 5
  start-page: 953
  year: 2019
  end-page: 960
  ident: bib98
  article-title: Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial
  publication-title: JAMA Oncol
– volume: 389
  start-page: 56
  year: 2017
  end-page: 66
  ident: bib106
  article-title: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet
– volume: 33
  start-page: 41
  year: 2010
  end-page: 52
  ident: bib56
  article-title: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study
  publication-title: Cardiovasc Intervent Radiol
– volume: 117
  start-page: 381
  year: 2018
  end-page: 403
  ident: bib11
  article-title: Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
  publication-title: J Formos Med Assoc
– volume: 5
  start-page: 511
  year: 2017
  end-page: 518
  ident: bib57
  article-title: Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials
  publication-title: United European Gastroenterol J
– volume: 60
  start-page: 1697
  year: 2014
  end-page: 1707
  ident: bib67
  article-title: Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial
  publication-title: Hepatology
– volume: 144
  start-page: 102
  year: 2013
  end-page: 111
  ident: bib46
  article-title: Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis
  publication-title: Gastroenterology
– volume: 23
  start-page: 331
  year: 2017
  end-page: 336
  ident: bib123
  article-title: Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature
  publication-title: Discov Med
– volume: 36
  start-page: 1913
  year: 2018
  end-page: 1921
  ident: bib74
  article-title: SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma
  publication-title: J Clin Oncol
– volume: 3
  start-page: 424
  year: 2018
  end-page: 432
  ident: bib96
  article-title: Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
  publication-title: Lancet Gastroenterol Hepatol
– volume: 5
  start-page: 8
  year: 2016
  end-page: 20
  ident: bib85
  article-title: The effectiveness of multiple electrode radiofrequency ablation in patients with hepatocellular carcinoma with lesions more than 3 cm in size and Barcelona Clinic Liver Cancer Stage A to B2
  publication-title: Liver Cancer
– volume: 38
  start-page: 1646
  year: 2018
  end-page: 1654
  ident: bib113
  article-title: Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein
  publication-title: Liver Int
– volume: 37
  start-page: 429
  year: 2003
  end-page: 442
  ident: bib55
  article-title: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival
  publication-title: Hepatology
– volume: 42
  start-page: 376
  year: 2012
  end-page: 384
  ident: bib23
  article-title: Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography
  publication-title: Hepatol Res
– volume: 295
  start-page: 65
  year: 2006
  end-page: 73
  ident: bib26
  article-title: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
  publication-title: JAMA
– volume: 47
  start-page: 2117
  year: 2011
  end-page: 2127
  ident: bib68
  article-title: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
  publication-title: Eur J Cancer
– volume: 275
  start-page: 97
  year: 2015
  end-page: 109
  ident: bib33
  article-title: Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis
  publication-title: Radiology
– volume: 82
  start-page: 469
  year: 2018
  end-page: 478
  ident: bib94
  article-title: Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
  publication-title: Cancer Chemother Pharmacol
– volume: 38
  start-page: 290
  year: 2013
  end-page: 296
  ident: bib35
  article-title: Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers
  publication-title: Abdom Imaging
– volume: 264
  start-page: 330
  year: 2016
  end-page: 338
  ident: bib47
  article-title: Quantitative assessment of the portal pressure for the liver surgery using serological tests
  publication-title: Ann Surg
– volume: 33
  start-page: 1780
  year: 2018
  end-page: 1786
  ident: bib93
  article-title: Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status
  publication-title: J Gastroenterol Hepatol
– volume: 36
  start-page: 3523
  year: 2016
  end-page: 3529
  ident: bib95
  article-title: Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
  publication-title: Anticancer Res
– volume: 18
  start-page: e143
  year: 2017
  end-page: e152
  ident: bib124
  article-title: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
  publication-title: Lancet Oncol
– volume: 68
  start-page: 485
  year: 2018
  end-page: 492
  ident: bib39
  article-title: Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules
  publication-title: J Hepatol
– volume: 19
  start-page: 940
  year: 2018
  end-page: 952
  ident: bib110
  article-title: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
  publication-title: Lancet Oncol
– volume: 336
  start-page: 1855
  year: 1997
  end-page: 1859
  ident: bib18
  article-title: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group
  publication-title: N Engl J Med
– volume: 63
  start-page: 743
  year: 2015
  end-page: 752
  ident: bib48
  article-title: Expanding consensus in portal hypertension: report of the BavenoVI Consensus workshop: stratifying risk and individualizing care for portal hypertension
  publication-title: J Hepatology
– volume: 13
  start-page: 227
  year: 2019
  end-page: 299
  ident: bib8
  article-title: 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma
  publication-title: Gut Liver
– volume: 44
  start-page: 195
  year: 2018
  end-page: 208
  ident: bib84
  article-title: The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review
  publication-title: Eur J Surg Oncol
– volume: 27
  start-page: 2090
  year: 2016
  end-page: 2096
  ident: bib97
  article-title: Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
  publication-title: Ann Oncol
– volume: 4
  start-page: 661
  year: 2018
  end-page: 669
  ident: bib115
  article-title: Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial
  publication-title: JAMA Oncol
– volume: 10
  start-page: 1111
  year: 2009
  end-page: 1118
  ident: bib13
  article-title: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009
  publication-title: Lancet Oncol
– volume: 146
  start-page: 1691
  year: 2014
  end-page: 1700.e3
  ident: bib14
  article-title: Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 58
  start-page: 1655
  year: 2013
  end-page: 1666
  ident: bib122
  article-title: Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90 ± sorafenib
  publication-title: Hepatology
– volume: 142
  start-page: 1140
  year: 2012
  end-page: 1149.e3
  ident: bib27
  article-title: High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load
  publication-title: Gastroenterology
– volume: 36
  start-page: 207
  year: 2018
  ident: bib107
  article-title: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial
  publication-title: J Clin Oncol
– volume: 130
  start-page: 417
  year: 2004
  end-page: 422
  ident: bib28
  article-title: Randomized controlled trial of screening for hepatocellular carcinoma
  publication-title: J Cancer Res Clin Oncol
– volume: 67
  start-page: 1204
  year: 2017
  end-page: 1212
  ident: bib21
  article-title: Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression
  publication-title: J Hepatol
– volume: 36
  start-page: 264
  year: 2011
  end-page: 272
  ident: bib34
  article-title: Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis
  publication-title: Abdom Imaging
– year: 2019
  ident: bib105
  article-title: Atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma: Phase 3 results from IMbrave150
  publication-title: ESMO Asia
– volume: 52
  start-page: 652
  year: 2010
  end-page: 657
  ident: bib19
  article-title: Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
  publication-title: J Hepatol
– volume: 35
  start-page: 1164
  year: 2002
  end-page: 1171
  ident: bib54
  article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
  publication-title: Hepatology
– volume: 108
  start-page: 1252
  year: 2013
  end-page: 1259
  ident: bib59
  article-title: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma
  publication-title: Br J Cancer
– volume: 57
  start-page: 1592
  year: 2008
  end-page: 1596
  ident: bib42
  article-title: Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis
  publication-title: Gut
– volume: 18
  start-page: 1624
  year: 2017
  end-page: 1636
  ident: bib73
  article-title: Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
  publication-title: Lancet Oncol
– volume: 37
  start-page: 1047
  year: 2017
  end-page: 1055
  ident: bib121
  article-title: mRECIST to predict survival in advanced hepatocellular carcinoma: analysis of two randomised phase II trials comparing nintedanib vs sorafenib
  publication-title: Liver Int
– volume: 68
  start-page: 977
  year: 2018
  end-page: 993
  ident: bib83
  article-title: Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies
  publication-title: Hepatology
– volume: 31
  start-page: 3501
  year: 2013
  end-page: 3508
  ident: bib88
  article-title: Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia
  publication-title: J Clin Oncol
– volume: 109
  start-page: 1904
  year: 2013
  end-page: 1907
  ident: bib92
  article-title: Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan
  publication-title: Br J Cancer
– volume: 11
  start-page: 389
  year: 2017
  end-page: 398
  ident: bib10
  article-title: The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines from 2001 to 2017
  publication-title: Biosci Trends
– volume: 34
  start-page: 2046
  year: 2016
  end-page: 2053
  ident: bib60
  article-title: Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone
  publication-title: J Clin Oncol
– volume: 11
  start-page: 334
  year: 2014
  end-page: 336
  ident: bib52
  article-title: Hepatocellular carcinoma: have we finally found the ultimate staging system for HCC?
  publication-title: Nat Rev Gastroeneterol Hepatol
– volume: 15
  start-page: 223
  year: 2011
  end-page: 243
  ident: bib2
  article-title: The global epidemiology of hepatocellular carcinoma: present and future
  publication-title: Clin Liver Dis
– year: 2019
  ident: bib15
  article-title: Hepatocellular carcinoma treatment recommendations
– volume: 6
  start-page: 753
  year: 2012
  end-page: 762
  ident: bib114
  article-title: Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis
  publication-title: Hepatol Int
– volume: 25
  start-page: 3069
  year: 2007
  end-page: 3075
  ident: bib87
  article-title: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin
  publication-title: J Clin Oncol
– volume: 20
  start-page: 282
  year: 2019
  end-page: 296
  ident: bib108
  article-title: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol
– volume: 33
  start-page: 541
  year: 2010
  end-page: 551
  ident: bib61
  article-title: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma
  publication-title: Cardiovasc Intervent Radiol
– volume: 3
  start-page: 37
  year: 2018
  end-page: 46
  ident: bib66
  article-title: Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
  publication-title: Lancet Gastroenterol Hepatol
– volume: 33
  start-page: 550
  year: 2015
  end-page: 558
  ident: bib44
  article-title: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade
  publication-title: J Clin Oncol
– volume: 10
  start-page: e0133488
  year: 2015
  ident: bib119
  article-title: Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis
  publication-title: PLoS One
– volume: 16
  start-page: 4
  year: 2016
  ident: bib49
  article-title: Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation
  publication-title: Cancer Imaging
– volume: 3
  start-page: 544
  year: 2009
  end-page: 550
  ident: bib29
  article-title: Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C
  publication-title: Hepatol Int
– volume: 30
  start-page: 6
  year: 2007
  end-page: 25
  ident: bib58
  article-title: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies
  publication-title: Cardiovasc Intervent Radiol
– volume: 45
  start-page: 720
  year: 2018
  end-page: 726
  ident: bib50
  article-title: Preoperative prediction of microvascular invasion of hepatocellular carcinoma using (18)F-FDG PET/CT: a multicenter retrospective cohort study
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 33
  start-page: 559
  year: 2015
  end-page: 566
  ident: bib103
  article-title: SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma
  publication-title: J Clin Oncol
– volume: 49
  start-page: 1017
  year: 2009
  end-page: 1044
  ident: bib41
  article-title: Liver biopsy
  publication-title: Hepatology
– volume: 56
  start-page: 1089
  year: 2012
  end-page: 1096
  ident: bib31
  article-title: Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population
  publication-title: J Hepatol
– volume: 24
  start-page: 965
  year: 2013
  end-page: 973
  ident: bib117
  article-title: mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
  publication-title: Ann Oncol
– volume: 62
  start-page: 363
  year: 2015
  end-page: 370
  ident: bib20
  article-title: Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
  publication-title: J Hepatol
– volume: 262
  start-page: 708
  year: 2012
  end-page: 718
  ident: bib118
  article-title: Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models
  publication-title: Radiology
– volume: 97
  start-page: 1532
  year: 2005
  end-page: 1538
  ident: bib89
  article-title: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
  publication-title: J Natl Cancer Inst
– volume: 3
  start-page: 458
  year: 2014
  end-page: 468
  ident: bib9
  article-title: JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan
  publication-title: Liver Cancer
– volume: 67
  start-page: 999
  year: 2017
  end-page: 1008
  ident: bib91
  article-title: Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies
  publication-title: J Hepatol
– volume: 31
  start-page: 4067
  year: 2013
  end-page: 4075
  ident: bib100
  article-title: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial
  publication-title: J Clin Oncol
– year: 2019
  ident: bib111
  article-title: Update on KEYNOTE-240, a phase 3 study of KEYTRUDA® (pembrolizumab) in previously treated patients with advanced hepatocellular carcinoma
– volume: 5
  start-page: 245
  year: 2016
  end-page: 256
  ident: bib82
  article-title: Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)
  publication-title: Liver Cancer
– volume: 116
  start-page: 1305
  year: 2010
  end-page: 1314
  ident: bib79
  article-title: Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study
  publication-title: Cancer
– volume: 61
  start-page: 589
  year: 2014
  end-page: 593
  ident: bib40
  article-title: Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC
  publication-title: J Hepatol
– volume: 29
  start-page: 44
  year: 2018
  end-page: 70
  ident: bib16
  article-title: Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
  publication-title: Ann Oncol
– volume: 17
  start-page: 261
  year: 2011
  end-page: 267
  ident: bib24
  article-title: Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk
  publication-title: J Eval Clin Pract
– volume: 66
  start-page: 1980
  year: 2017
  end-page: 1988
  ident: bib51
  article-title: Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease
  publication-title: Hepatology
– volume: 391
  start-page: 1163
  year: 2018
  end-page: 1173
  ident: bib104
  article-title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
  publication-title: Lancet
– volume: 36
  start-page: 648
  year: 2012
  end-page: 657
  ident: bib36
  article-title: Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration
  publication-title: J Magn Reson Imaging
– volume: 151
  start-page: 1155
  year: 2016
  end-page: 1163.e2
  ident: bib76
  article-title: Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 28
  start-page: 2340
  year: 2017
  end-page: 2366
  ident: bib125
  article-title: ESMO-Magnitude of Clinical Benefit Scale version 1.1
  publication-title: Ann Oncol
– volume: 101
  start-page: 422
  year: 1996
  end-page: 434
  ident: bib22
  article-title: Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis
  publication-title: Am J Med
– volume: 59
  start-page: 1840
  year: 2014
  end-page: 1849
  ident: bib30
  article-title: Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan
  publication-title: Hepatology
– volume: 359
  start-page: 1734
  year: 2002
  end-page: 1739
  ident: bib53
  article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
  publication-title: Lancet
– volume: 30
  start-page: 52
  year: 2010
  end-page: 60
  ident: bib90
  article-title: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
  publication-title: Semin Liver Dis
– volume: 17
  start-page: 98
  year: 2017
  ident: bib112
  article-title: Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience
  publication-title: BMC Gastroenterol
– volume: 197
  start-page: 58
  year: 2011
  end-page: 63
  ident: bib37
  article-title: Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI
  publication-title: AJR Am J Roentgenol
– volume: 9
  start-page: e100305
  year: 2014
  ident: bib64
  article-title: Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis
  publication-title: PLoS One
– volume: 9
  start-page: 1920
  year: 2009
  end-page: 1928
  ident: bib75
  article-title: A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization
  publication-title: Am J Transplant
– volume: 66
  start-page: 1166
  year: 2017
  end-page: 1172
  ident: bib120
  article-title: Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
  publication-title: J Hepatol
– volume: 328
  start-page: 1797
  year: 1993
  end-page: 1801
  ident: bib25
  article-title: Risk factors for hepatocellular carcinoma among patients with chronic liver disease
  publication-title: N Engl J Med
– volume: 140
  start-page: 497
  year: 2011
  end-page: 507.e2
  ident: bib77
  article-title: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 31
  start-page: 3517
  year: 2013
  end-page: 3524
  ident: bib102
  article-title: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study
  publication-title: J Clin Oncol
– volume: 33
  start-page: 139
  year: 2001
  end-page: 144
  ident: bib17
  article-title: Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
  publication-title: Clin Infect Dis
– volume: 58
  start-page: 2188
  year: 2013
  end-page: 2197
  ident: bib72
  article-title: Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives
  publication-title: Hepatology
– volume: 389
  start-page: 2492
  year: 2017
  end-page: 2502
  ident: bib109
  article-title: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
  publication-title: Lancet
– volume: 49
  start-page: 658
  year: 2009
  end-page: 664
  ident: bib43
  article-title: Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia
  publication-title: Hepatology
– volume: 10
  start-page: 25
  year: 2009
  end-page: 34
  ident: bib62
  article-title: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
  publication-title: Lancet Oncol
– volume: 70
  start-page: 684
  year: 2019
  end-page: 691
  ident: bib70
  article-title: Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial
  publication-title: J Hepatol
– volume: 5
  start-page: 953
  year: 2019
  ident: 10.1016/j.annonc.2019.12.001_bib98
  article-title: Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2019.0250
– volume: 11
  start-page: 389
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib10
  article-title: The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines from 2001 to 2017
  publication-title: Biosci Trends
  doi: 10.5582/bst.2017.01202
– volume: 10
  start-page: 1111
  year: 2009
  ident: 10.1016/j.annonc.2019.12.001_bib13
  article-title: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70241-4
– volume: 31
  start-page: 4067
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib100
  article-title: Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.45.8372
– volume: 7
  start-page: 1708
  year: 2015
  ident: 10.1016/j.annonc.2019.12.001_bib7
  article-title: Hepatocellular carcinoma in Asia: prevention strategy and planning
  publication-title: World J Hepatol
  doi: 10.4254/wjh.v7.i12.1708
– volume: 151
  start-page: 1155
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib76
  article-title: Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.08.029
– volume: 359
  start-page: 1734
  year: 2002
  ident: 10.1016/j.annonc.2019.12.001_bib53
  article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08649-X
– volume: 32
  start-page: 695
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib86
  article-title: Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/jgh.13586
– volume: 5
  start-page: 511
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib57
  article-title: Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials
  publication-title: United European Gastroenterol J
  doi: 10.1177/2050640616673516
– volume: 68
  start-page: 485
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib39
  article-title: Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.11.007
– volume: 6
  start-page: 238
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib71
  article-title: Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
  publication-title: United European Gastroenterol J
  doi: 10.1177/2050640617716597
– volume: 38
  start-page: 290
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib35
  article-title: Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers
  publication-title: Abdom Imaging
  doi: 10.1007/s00261-012-9952-9
– volume: 117
  start-page: 381
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib11
  article-title: Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
  publication-title: J Formos Med Assoc
  doi: 10.1016/j.jfma.2017.09.007
– volume: 32
  start-page: 678
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib38
  article-title: Non-hypervascular hypointense nodules ≥1 cm on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in cirrhotic livers
  publication-title: Dig Dis
  doi: 10.1159/000368000
– volume: 389
  start-page: 2492
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib109
  article-title: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)31046-2
– volume: 328
  start-page: 1797
  year: 1993
  ident: 10.1016/j.annonc.2019.12.001_bib25
  article-title: Risk factors for hepatocellular carcinoma among patients with chronic liver disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199306243282501
– volume: 70
  start-page: 684
  year: 2019
  ident: 10.1016/j.annonc.2019.12.001_bib70
  article-title: Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.11.029
– volume: 49
  start-page: 658
  year: 2009
  ident: 10.1016/j.annonc.2019.12.001_bib43
  article-title: Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia
  publication-title: Hepatology
  doi: 10.1002/hep.22709
– volume: 24
  start-page: 965
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib117
  article-title: mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mds605
– volume: 37
  start-page: 429
  year: 2003
  ident: 10.1016/j.annonc.2019.12.001_bib55
  article-title: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival
  publication-title: Hepatology
  doi: 10.1053/jhep.2003.50047
– volume: 67
  start-page: 1204
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib21
  article-title: Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.07.025
– volume: 17
  start-page: 98
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib112
  article-title: Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience
  publication-title: BMC Gastroenterol
  doi: 10.1186/s12876-017-0656-z
– year: 2019
  ident: 10.1016/j.annonc.2019.12.001_bib105
  article-title: Atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma: Phase 3 results from IMbrave150
  publication-title: ESMO Asia
– volume: 29
  start-page: 44
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib16
  article-title: Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx738
– volume: 64
  start-page: 1090
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib69
  article-title: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2016.01.012
– volume: 389
  start-page: 56
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib106
  article-title: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32453-9
– volume: 27
  start-page: 1213
  year: 2012
  ident: 10.1016/j.annonc.2019.12.001_bib45
  article-title: Transient elastography and simple blood markers in the diagnosis of oesophageal varices for compensated patients with hepatitis B virus-related cirrhosis
  publication-title: J Gasterenterol Hepatol
  doi: 10.1111/j.1440-1746.2012.07132.x
– volume: 108
  start-page: 1252
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib59
  article-title: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.85
– volume: 52
  start-page: 652
  year: 2010
  ident: 10.1016/j.annonc.2019.12.001_bib19
  article-title: Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2009.12.028
– volume: 3
  start-page: 544
  year: 2009
  ident: 10.1016/j.annonc.2019.12.001_bib29
  article-title: Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C
  publication-title: Hepatol Int
  doi: 10.1007/s12072-009-9145-y
– volume: 13
  start-page: 227
  year: 2019
  ident: 10.1016/j.annonc.2019.12.001_bib8
  article-title: 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma
  publication-title: Gut Liver
  doi: 10.5009/gnl19024
– volume: 2
  start-page: 565
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib65
  article-title: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(17)30156-5
– volume: 58
  start-page: 2188
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib72
  article-title: Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives
  publication-title: Hepatology
  doi: 10.1002/hep.26382
– volume: 36
  start-page: 207
  issue: suppl 4
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib107
  article-title: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.36.4_suppl.207
– volume: 36
  start-page: 1913
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib74
  article-title: SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.76.0892
– volume: 55
  start-page: 1309
  year: 2011
  ident: 10.1016/j.annonc.2019.12.001_bib116
  article-title: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2011.03.007
– volume: 31
  start-page: 3501
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib88
  article-title: Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.44.5643
– volume: 5
  start-page: 8
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib85
  article-title: The effectiveness of multiple electrode radiofrequency ablation in patients with hepatocellular carcinoma with lesions more than 3 cm in size and Barcelona Clinic Liver Cancer Stage A to B2
  publication-title: Liver Cancer
  doi: 10.1159/000367755
– volume: 11
  start-page: 334
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib52
  article-title: Hepatocellular carcinoma: have we finally found the ultimate staging system for HCC?
  publication-title: Nat Rev Gastroeneterol Hepatol
  doi: 10.1038/nrgastro.2014.67
– volume: 57
  start-page: 1592
  year: 2008
  ident: 10.1016/j.annonc.2019.12.001_bib42
  article-title: Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis
  publication-title: Gut
  doi: 10.1136/gut.2008.149062
– volume: 44
  start-page: 195
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib84
  article-title: The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2017.11.022
– volume: 29
  start-page: iv238
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib3
  article-title: Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy308
– volume: 56
  start-page: 1089
  year: 2012
  ident: 10.1016/j.annonc.2019.12.001_bib31
  article-title: Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2011.11.022
– volume: 15
  start-page: 223
  year: 2011
  ident: 10.1016/j.annonc.2019.12.001_bib2
  article-title: The global epidemiology of hepatocellular carcinoma: present and future
  publication-title: Clin Liver Dis
  doi: 10.1016/j.cld.2011.03.006
– volume: 7
  start-page: 235
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib12
  article-title: Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition)
  publication-title: Liver Cancer
  doi: 10.1159/000488035
– volume: 27
  start-page: 2090
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib97
  article-title: Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw323
– volume: 60
  start-page: 1697
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib67
  article-title: Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial
  publication-title: Hepatology
  doi: 10.1002/hep.27290
– volume: 87
  start-page: 22
  issue: suppl 1
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib81
  article-title: Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update
  publication-title: Oncology
  doi: 10.1159/000368142
– volume: 30
  start-page: 52
  year: 2010
  ident: 10.1016/j.annonc.2019.12.001_bib90
  article-title: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
  publication-title: Semin Liver Dis
  doi: 10.1055/s-0030-1247132
– volume: 6
  start-page: 101
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib99
  article-title: Molecular targeted agents for hepatocellular carcinoma: current status and future perspectives
  publication-title: Liver Cancer
  doi: 10.1159/000452138
– volume: 10
  start-page: e0133488
  year: 2015
  ident: 10.1016/j.annonc.2019.12.001_bib119
  article-title: Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0133488
– volume: 49
  start-page: 1017
  year: 2009
  ident: 10.1016/j.annonc.2019.12.001_bib41
  article-title: Liver biopsy
  publication-title: Hepatology
  doi: 10.1002/hep.22742
– volume: 6
  start-page: 753
  year: 2012
  ident: 10.1016/j.annonc.2019.12.001_bib114
  article-title: Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis
  publication-title: Hepatol Int
  doi: 10.1007/s12072-011-9322-7
– volume: 33
  start-page: 139
  year: 2001
  ident: 10.1016/j.annonc.2019.12.001_bib17
  article-title: Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
  publication-title: Clin Infect Dis
  doi: 10.1086/321805
– volume: 105
  start-page: 1430
  year: 2011
  ident: 10.1016/j.annonc.2019.12.001_bib5
  article-title: Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.360
– volume: 3
  start-page: 424
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib96
  article-title: Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(18)30078-5
– volume: 4
  start-page: 661
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib115
  article-title: Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2017.5847
– volume: 275
  start-page: 97
  year: 2015
  ident: 10.1016/j.annonc.2019.12.001_bib33
  article-title: Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis
  publication-title: Radiology
  doi: 10.1148/radiol.14140690
– volume: 36
  start-page: 648
  year: 2012
  ident: 10.1016/j.annonc.2019.12.001_bib36
  article-title: Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration
  publication-title: J Magn Reson Imaging
  doi: 10.1002/jmri.23685
– volume: 61
  start-page: 589
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib40
  article-title: Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2014.04.046
– volume: 62
  start-page: 363
  year: 2015
  ident: 10.1016/j.annonc.2019.12.001_bib20
  article-title: Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2014.08.045
– volume: 144
  start-page: 102
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib46
  article-title: Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2012.10.001
– volume: 58
  start-page: 1655
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib122
  article-title: Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90 ± sorafenib
  publication-title: Hepatology
  doi: 10.1002/hep.26487
– volume: 116
  start-page: 1305
  year: 2010
  ident: 10.1016/j.annonc.2019.12.001_bib79
  article-title: Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study
  publication-title: Cancer
  doi: 10.1002/cncr.24884
– volume: 36
  start-page: 3523
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib95
  article-title: Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
  publication-title: Anticancer Res
– volume: 68
  start-page: S102
  issue: suppl 1
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib78
  article-title: The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the Soramic trial paliative cohort
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(18)30424-0
– volume: 47
  start-page: 97
  year: 2008
  ident: 10.1016/j.annonc.2019.12.001_bib32
  article-title: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.21966
– volume: 23
  start-page: 331
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib123
  article-title: Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature
  publication-title: Discov Med
– volume: 25
  start-page: 3069
  year: 2007
  ident: 10.1016/j.annonc.2019.12.001_bib87
  article-title: Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.4046
– volume: 17
  start-page: 261
  year: 2011
  ident: 10.1016/j.annonc.2019.12.001_bib24
  article-title: Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk
  publication-title: J Eval Clin Pract
  doi: 10.1111/j.1365-2753.2010.01432.x
– volume: 109
  start-page: 1904
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib92
  article-title: Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.542
– volume: 33
  start-page: 550
  year: 2015
  ident: 10.1016/j.annonc.2019.12.001_bib44
  article-title: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.9151
– volume: 9
  start-page: e100305
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib64
  article-title: Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0100305
– volume: 30
  start-page: 6
  year: 2007
  ident: 10.1016/j.annonc.2019.12.001_bib58
  article-title: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies
  publication-title: Cardiovasc Intervent Radiol
  doi: 10.1007/s00270-006-0062-3
– volume: 66
  start-page: 1980
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib51
  article-title: Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease
  publication-title: Hepatology
  doi: 10.1002/hep.29363
– volume: 295
  start-page: 65
  year: 2006
  ident: 10.1016/j.annonc.2019.12.001_bib26
  article-title: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
  publication-title: JAMA
  doi: 10.1001/jama.295.1.65
– volume: 10
  start-page: 25
  year: 2009
  ident: 10.1016/j.annonc.2019.12.001_bib62
  article-title: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(08)70285-7
– volume: 13
  start-page: 398
  year: 1991
  ident: 10.1016/j.annonc.2019.12.001_bib4
  article-title: Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.1840130303
– volume: 142
  start-page: 1140
  year: 2012
  ident: 10.1016/j.annonc.2019.12.001_bib27
  article-title: High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2012.02.007
– volume: 130
  start-page: 417
  year: 2004
  ident: 10.1016/j.annonc.2019.12.001_bib28
  article-title: Randomized controlled trial of screening for hepatocellular carcinoma
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-004-0552-0
– volume: 19
  start-page: 940
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib110
  article-title: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30351-6
– volume: 197
  start-page: 58
  year: 2011
  ident: 10.1016/j.annonc.2019.12.001_bib37
  article-title: Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/AJR.10.5390
– volume: 5
  start-page: 245
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib82
  article-title: Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)
  publication-title: Liver Cancer
  doi: 10.1159/000449336
– volume: 28
  start-page: 2340
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib125
  article-title: ESMO-Magnitude of Clinical Benefit Scale version 1.1
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx310
– volume: 68
  start-page: 394
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21492
– volume: 33
  start-page: 541
  year: 2010
  ident: 10.1016/j.annonc.2019.12.001_bib61
  article-title: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma
  publication-title: Cardiovasc Intervent Radiol
  doi: 10.1007/s00270-009-9750-0
– volume: 146
  start-page: 1691
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib14
  article-title: Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2014.02.032
– volume: 3
  start-page: 37
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib66
  article-title: Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(17)30290-X
– volume: 20
  start-page: 282
  year: 2019
  ident: 10.1016/j.annonc.2019.12.001_bib108
  article-title: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30937-9
– volume: 140
  start-page: 497
  year: 2011
  ident: 10.1016/j.annonc.2019.12.001_bib77
  article-title: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.10.049
– volume: 262
  start-page: 708
  year: 2012
  ident: 10.1016/j.annonc.2019.12.001_bib118
  article-title: Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models
  publication-title: Radiology
  doi: 10.1148/radiol.11110282
– volume: 42
  start-page: 376
  year: 2012
  ident: 10.1016/j.annonc.2019.12.001_bib23
  article-title: Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography
  publication-title: Hepatol Res
  doi: 10.1111/j.1872-034X.2011.00936.x
– volume: 36
  start-page: 264
  year: 2011
  ident: 10.1016/j.annonc.2019.12.001_bib34
  article-title: Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis
  publication-title: Abdom Imaging
  doi: 10.1007/s00261-011-9685-1
– volume: 66
  start-page: 1166
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib120
  article-title: Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.01.012
– volume: 3
  start-page: 458
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib9
  article-title: JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan
  publication-title: Liver Cancer
  doi: 10.1159/000343875
– volume: 16
  start-page: 4
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib49
  article-title: Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation
  publication-title: Cancer Imaging
  doi: 10.1186/s40644-016-0062-8
– volume: 359
  start-page: 378
  year: 2008
  ident: 10.1016/j.annonc.2019.12.001_bib63
  article-title: Sorafenib in advanced hepatocellular carcinoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0708857
– volume: 18
  start-page: e143
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib124
  article-title: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30074-8
– volume: 63
  start-page: 743
  year: 2015
  ident: 10.1016/j.annonc.2019.12.001_bib48
  article-title: Expanding consensus in portal hypertension: report of the BavenoVI Consensus workshop: stratifying risk and individualizing care for portal hypertension
  publication-title: J Hepatology
  doi: 10.1016/j.jhep.2015.05.022
– volume: 37
  start-page: 1047
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib121
  article-title: mRECIST to predict survival in advanced hepatocellular carcinoma: analysis of two randomised phase II trials comparing nintedanib vs sorafenib
  publication-title: Liver Int
  doi: 10.1111/liv.13359
– volume: 35
  start-page: 1164
  year: 2002
  ident: 10.1016/j.annonc.2019.12.001_bib54
  article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1053/jhep.2002.33156
– volume: 336
  start-page: 1855
  year: 1997
  ident: 10.1016/j.annonc.2019.12.001_bib18
  article-title: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199706263362602
– volume: 101
  start-page: 422
  year: 1996
  ident: 10.1016/j.annonc.2019.12.001_bib22
  article-title: Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis
  publication-title: Am J Med
  doi: 10.1016/S0002-9343(96)00197-0
– volume: 67
  start-page: 999
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib91
  article-title: Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.06.026
– volume: 82
  start-page: 469
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib94
  article-title: Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-018-3638-0
– volume: 264
  start-page: 330
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib47
  article-title: Quantitative assessment of the portal pressure for the liver surgery using serological tests
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000001460
– volume: 11
  start-page: 317
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib6
  article-title: Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
  publication-title: Hepatol Int
  doi: 10.1007/s12072-017-9799-9
– volume: 59
  start-page: 1840
  year: 2014
  ident: 10.1016/j.annonc.2019.12.001_bib30
  article-title: Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan
  publication-title: Hepatology
  doi: 10.1002/hep.26703
– volume: 97
  start-page: 1532
  year: 2005
  ident: 10.1016/j.annonc.2019.12.001_bib89
  article-title: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dji315
– volume: 33
  start-page: 559
  year: 2015
  ident: 10.1016/j.annonc.2019.12.001_bib103
  article-title: SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.53.7746
– volume: 391
  start-page: 1163
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib104
  article-title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)30207-1
– volume: 38
  start-page: 1646
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib113
  article-title: Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein
  publication-title: Liver Int
  doi: 10.1111/liv.13719
– volume: 68
  start-page: 977
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib83
  article-title: Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies
  publication-title: Hepatology
  doi: 10.1002/hep.29883
– volume: 33
  start-page: 1780
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib93
  article-title: Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/jgh.14152
– volume: 34
  start-page: 2046
  year: 2016
  ident: 10.1016/j.annonc.2019.12.001_bib60
  article-title: Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.64.0821
– volume: 57
  start-page: 1826
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib80
  article-title: Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study
  publication-title: Hepatology
  doi: 10.1002/hep.26014
– volume: 33
  start-page: 172
  year: 2015
  ident: 10.1016/j.annonc.2019.12.001_bib101
  article-title: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.54.3298
– volume: 31
  start-page: 3517
  year: 2013
  ident: 10.1016/j.annonc.2019.12.001_bib102
  article-title: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.48.4410
– volume: 9
  start-page: 1920
  year: 2009
  ident: 10.1016/j.annonc.2019.12.001_bib75
  article-title: A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization
  publication-title: Am J Transplant
  doi: 10.1111/j.1600-6143.2009.02695.x
– volume: 45
  start-page: 720
  year: 2018
  ident: 10.1016/j.annonc.2019.12.001_bib50
  article-title: Preoperative prediction of microvascular invasion of hepatocellular carcinoma using (18)F-FDG PET/CT: a multicenter retrospective cohort study
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-017-3880-4
– volume: 47
  start-page: 2117
  year: 2011
  ident: 10.1016/j.annonc.2019.12.001_bib68
  article-title: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2011.05.007
– volume: 18
  start-page: 1624
  year: 2017
  ident: 10.1016/j.annonc.2019.12.001_bib73
  article-title: Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30683-6
– volume: 33
  start-page: 41
  year: 2010
  ident: 10.1016/j.annonc.2019.12.001_bib56
  article-title: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study
  publication-title: Cardiovasc Intervent Radiol
  doi: 10.1007/s00270-009-9711-7
– reference: 32122696 - Ann Oncol. 2020 Apr;31(4):449-450
SSID ssj0006929
Score 2.6527536
Snippet The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 334
SubjectTerms Asia
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - therapy
China
consensus
ESMO guidelines
HCC
hepatocellular carcinoma
Humans
India
Japan
Liver Neoplasms - diagnosis
Liver Neoplasms - therapy
Malaysia
Medical Oncology
Pan-Asian
Republic of Korea
Taiwan
Title Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
URI https://dx.doi.org/10.1016/j.annonc.2019.12.001
https://www.ncbi.nlm.nih.gov/pubmed/32067677
https://www.proquest.com/docview/2357471439
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals - Free Access to All
  customDbUrl:
  eissn: 1569-8041
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0006929
  issn: 0923-7534
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1569-8041
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0006929
  issn: 0923-7534
  databaseCode: GX1
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9NAEMdXoUiIC-JNeGmQEBeypX7H3KKQqrRJHSmJlJu1fkRQUTskzgG-Kl-Cj8DMPhyHtmrh4liWnd1oftmdXf9nhrG3mRMmgZXnPEuFx10nzzhOeha30tBKvcTuWnK_Y3TqH83c47k3b7V-N1RLmyrZT39eGlfyP1bFa2hXipL9B8vWX4oX8Bzti0e0MB5vZOOxKHhPRkGKTCzJdxxMRtH7vol2HOsQKASBslmRwr2WFZ7XuhcpelbpVXWsG-WQWMmYkkq9XTBKAewqBb8s19jUF5zIqpI2_qWSNaWiREV5LlT49DSacNmZr6ROUtnF8yIrV2vl8vYn_UiOT5PRWJ4c481y1NGfo2iiZKWTqOlAbxM-l0W680qgr-NMhrzWfascCZRy9K-Yi1yNcD0-3E4NBbnC5SYjl1q-LWhuiODqt1aEmTHcDzmlVVJT3CXX9MDvWA3AncYo7qj91Quzi9roONsXRYG_kXSBodxL1q3vJPM-jeLD2XAYTwfz6bvld051zkgPoIu-3GK37cD3qebGp88nte_gh7KuXt1dE-wpFYkXm73KmbpqsSSdpul9dk-vdqCn0H3AWnnxkN0ZaT3HI_arJhg0wUDQgCEYDMGwJRiQYEBbwZZgKBdgCAYiGJoEA2IEhuAPhl_Y5Rdqfj-CAEMvbOkFQy8kP4Do7YBktwNEbgdO5BGplc0htY_Z7HAw7R9xXW6Ep-jFVaRK9m03cBYHXuIlCy8Nu-gOuHYeuCFOjK5nC9HF5UKauEmSoGsvUsfCM7wrD3LhOU_YHhoof8YgO1gEXTdJw0zYrpPZwhcLu2svHPQYM8vP2swxdotTnYufSsJ8i43o8ixW1o7J2rFlk_a0zXj91FLlornm_sAgEWt_WvnJMQJ9zZNvDEExTjdkClHk5WYdU3Ys9GdxGdNmTxVadV8cKgXhB8HzGzz9gt3d_ndfsr1qtclfoXtfJa_lP-IP7dD7lg
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pan-Asian+adapted+ESMO+Clinical+Practice+Guidelines+for+the+management+of+patients+with+intermediate+and+advanced%2Frelapsed+hepatocellular+carcinoma%3A+a+TOS-ESMO+initiative+endorsed+by+CSCO%2C+ISMPO%2C+JSMO%2C+KSMO%2C+MOS+and+SSO&rft.jtitle=Annals+of+oncology&rft.au=Chen%2C+L-T&rft.au=Martinelli%2C+E&rft.au=Cheng%2C+A-L&rft.au=Pentheroudakis%2C+G&rft.date=2020-03-01&rft.issn=1569-8041&rft.eissn=1569-8041&rft.volume=31&rft.issue=3&rft.spage=334&rft_id=info:doi/10.1016%2Fj.annonc.2019.12.001&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon